Sangeeta Bhatia is a senior associate member of the Broad Institute, where she leads the effort to apply micro- and nanotechnology to tissue repair. A pioneer in the fields of tissue engineering, biomedical microdevices, and nanobiotechnology, Bhatia’s findings have produced high-throughput-capable human microlivers, which model human drug metabolism, drug-induced liver disease, and interaction with human pathogens. Her group also develops nanoparticles and nanoporous materials that can be designed to assemble and communicate to perform complex tasks such as seek out tumor cells, sense changes in cells and tissues, enhance imaging, and trigger the release of a therapeutic payload.
In addition to her role at the Broad, Bhatia directs the Laboratory for Multiscale Regenerative Technologies at MIT. She is also a Howard Hughes Medical Institute Investigator and the John J. and Dorothy Wilson Professor of Health Sciences and Technology (HST), Electrical Engineering and Computer Science (EECS) and Institute for Medical Engineering and Science (IMES) at MIT. She is a member of the Koch Institute for Integrative Cancer Research and the Harvard Stem Cell Institute, and a biomedical engineer at the Brigham & Women's Hospital.
She is a fellow of the American Institute for Medical and Biological Engineering, the Biomedical Engineering Society, and the American Society for Clinical Investigation. She has been awarded the David and Lucile Packard Fellowship given to "the nation's most promising young professors in science and engineering," the NSF CAREER Award, the Y.C. Fung Young Investigator Award of the American Society of Mechanical Engineers, the Young Investigator Award of the American College of Clinical Pharmacology, and the Brown Engineering Alumni Medal. She has been the recipient of the Harvard Medical School Diversity Award and the Harvard-MIT Thomas McMahon Mentoring Award. She co-authored the first undergraduate textbook on tissue engineering and is a frequent advisor to governmental organizations. Bhatia has published over 150 manuscripts, which were cited more than 3,100 times in 2012 and 2013, bringing her cumulative total to over 11,000 citations. She and her more than 150 trainees have contributed to more than 40 issued or pending patents (cancer nanotechnology, regenerative medicine, bioMEMS), 21 licensed products, and launched 9 biotechnology companies including Hepregen, Zymera, Sienna, Cell2B, and Seres.
Bhatia holds a B.S. from Brown University; an M.S. in medical engineering from MIT; a Ph.D. in biomedical engineering from MIT, and an M.D. from Harvard Medical School.